Ekso Bionics Holdings, Inc. — Q1 2016 Form 10-Q
Business and period: The filing is for the three months ended March 31, 2016; the financial statements are unaudited. Ekso designs, develops and sells exoskeletons for medical, industrial, military and other markets. The filing identifies Ekso Bionics Holdings, Inc. as the registrant; this differs from the “Chronoscale Holdings Corp” company name in the request metadata. Dollar amounts below are in millions unless noted.
Financial results and position
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Revenue | $8.486 | $1.689; up 402% |
| Medical device revenue | $8.057 | $0.985; up 718% |
| Engineering services revenue | $0.429 | $0.704; down 39% |
| Gross profit / margin | $1.498 / 17.7% | $0.403 / 23.9% |
| Operating expenses | $8.140 | $4.496; up 81% |
| Operating loss | $(6.642) | $(4.093) |
| Net loss | $(3.651) | $(4.115) |
| Net loss applicable to common shareholders / loss per share | $(6.775) / $(0.44) | $(4.115) / $(0.28) |
| Cash from operating activities | $(6.789) | $(3.828) |
Q1 2016 net loss included a $2.985 non-cash gain from revaluing warrants; common-shareholder loss also included a $3.124 non-cash preferred deemed dividend. The accounting change described below reduced common-shareholder loss by $2.358, or $0.15 per share.
At March 31, cash was $12.314, down from $19.552 at December 31, 2015. Current assets were $18.221 and current liabilities $7.849 (current ratio approximately 2.3). Total assets were $22.551, total liabilities $15.798, and stockholders’ equity $6.753. The balance sheet reports $0.206 of present-value note and capital lease obligations; separate fixed operating lease and supply commitments totaled $1.250. The filing reports no material legal proceedings.
Material changes and unusual items
- Revenue recognition: Beginning January 1, 2016, the company began accounting separately for the device and extended maintenance/support. It recognized $6.517 of previously deferred device revenue and $4.159 of related cost for devices already delivered, producing $2.358 of additional gross profit. This change materially lifted reported Q1 revenue and earnings and limits direct comparability with Q1 2015.
- Service and warranty accruals: The company recorded a one-time $0.911 charge for planned maintenance and upgrades to pre-2016 devices and accrued $0.212 of warranty expense. These items reduced device gross profit.
- Costs and compensation: Sales and marketing rose 35%, R&D 119%, and G&A 110% year over year. R&D included $0.5 of industrial-product spending ahead of a planned first-half 2016 launch. G&A included a $0.3 severance expense and $0.8 of incremental non-cash stock compensation from former CEO option modifications.
- Capital structure: Four preferred shares converted into common stock during the quarter, triggering the $3.124 deemed dividend. As a subsequent event, the company effected a 1-for-7 reverse stock split on May 4, 2016 to help meet Nasdaq’s minimum share-price requirement; Nasdaq listing approval was not assured. Share and per-share amounts in the filing reflect the split.
Outlook, risks and contingencies
Management estimated net cash use at approximately $1.8 per month based on its current 12-month average and said available resources were expected to cover obligations into the first quarter of 2017, assuming revenue increases and planned spending. The company also said it would require significant additional financing, which it intended to pursue by year-end through collaborations, equity or debt financing, or warrant solicitations. Financing availability and terms were uncertain; failure to obtain funding could require substantial expense reductions or curtailed operations.
Management planned continued investment in clinical, sales and marketing initiatives; development of a home-use exoskeleton; and industrial products. Risks include adoption and sales execution, long and variable sales cycles, competition, product development and clinical progress, regulation and reimbursement, intellectual property, financing needs, and foreign-currency exposure. The company said the FDA cleared Ekso GT on April 4, 2016 for specified stroke and spinal-cord-injury uses. The FDA had accepted the company’s corrective actions addressing four Form 483 inspection observations on March 30, 2016. The company also disclosed seven reportable device events since July 1, 2015, with no reported patient injuries.
Important facts for investors to verify
- How much of Q1’s revenue and gross profit reflected the accounting change and prior-period device deliveries, versus new Q1 sales?
- Whether the company’s cash runway and stated financing plans were borne out, given $6.789 of quarterly operating cash use and planned spending.
- Whether margins can improve as medical device sales scale, after the reported 17.7% consolidated gross margin and maintenance/warranty charges.
- Progress in commercialization after FDA clearance, including device adoption, sales cycles, rentals, and any subsequent safety or regulatory developments.
- Potential dilution from outstanding preferred shares, warrants and options, and the outcome of the proposed Nasdaq listing.